RxDoctor Payments Data

Alexander Kuley, MD

Ophthalmology · Cincinnati, OHNPI 1184043473

Payments from drug & device makers

$2,558in general payments, 2019–2025

Across 61 payments — averaging $41.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$806
  • Regeneron Healthcare Solutions, Inc.$366
  • Astellas Pharma US Inc$318
  • Alcon$154
  • Johnson & Johnson Surgical Vision, Inc.$120
  • AbbVie$119
  • plus $675 from 12 others

What the payments were for

  • Travel & lodging$80632%
  • Food & beverage$1,65465%
  • Education$984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,558 in reported general payments places this provider in the 65th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$790,803
Medicare patients
968
Services billed
9,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine25$32,537
XiidraLifitegrast24$26,363
LumiganBimatoprost54$16,767
RocklatanNetarsudil Mesylat/Latanoprost25$9,668
CombiganBrimonidine Tartrate/Timolol13$3,896
RhopressaNetarsudil Mesylate12$3,773
Prednisolone Acetate138$3,589
SimbrinzaBrinzolamide/Brimonidine Tart11$3,441
Alphagan PBrimonidine Tartrate16$3,038
Timolol Maleate181$3,004
Latanoprost380$2,303
Travoprost14$1,991
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat170$1,592
Brimonidine Tartrate156$1,113
Ketorolac Tromethamine58$1,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$119$56,239108 claims
Bausch & Lomb Americas Inc.Xiidra$41$26,36324 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$19$13,44137 claims
AlconSimbrinza$154$3,44111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →